The invention relates to a fusion protein containing a selective cell death-inducing enzyme system . The fusion comprises a modified, non-functional caspase that, once introduced in the cells, can be cleaved into an active form which then induces apoptosis of the cell. The modification of the caspase replaces its normal cleavage site with one that is the substrate of the protease of Tobacco Etch Virus. Uses of such a fusion protein, and of nucleic acids encoding it, in the tratment of cancer and tumors are contemplated.L'invention concerne une protéine hybride contenant un système enzymatique sélectif induisant la mort cellulaire, utilisable dans la thérapie et/ou le traitement du cancer et de tumeurs chez l'homme et l'animal. Elle concerne un procédé et l'utilisation de la protéine hybride.
